Literature DB >> 19427027

Identification of an active site of EMMPRIN for the augmentation of matrix metalloproteinase-1 and -3 expression in a co-culture of human uterine cervical carcinoma cells and fibroblasts.

Takashi Sato1, Tomoko Ota, Mami Watanabe, Keisuke Imada, Motoyoshi Nomizu, Akira Ito.   

Abstract

OBJECTIVE: Extracellular matrix metalloproteinase inducer (EMMPRIN) is highly expressed on malignant tumor cell surface and accelerates tumor invasion. We previously reported that human uterine cervical carcinoma SKG-II cells exhibit the progression of in-vitro invasiveness by utilizing the enhanced production of matrix metalloproteinase (MMP) in human uterine cervical fibroblasts (HUCF) under an in-vitro co-culture model (Sato T et al., Gynecol Oncol 2004; 92:47-56). The aim of this study was to clarify the active site of EMMPRIN in the augmentation of MMP production in the co-culture of SKG-II cells and HUCF.
METHODS: Western and Northern blot analyses were used to examine EMMPRIN and MMP expression in a co-culture of SKG-II cells or EMMPRIN-transfected COS-7 cells and HUCF. A systematic peptide screening method using nine synthetic EMMPRIN peptides was used to identify active site(s) of EMMPRIN for MMP induction.
RESULTS: SKG-II cells constitutively expressed 53-kDa EMMPRIN on the cell surface and EMMPRIN production was enhanced under the co-culture. The concomitant augmentation of proMMP-3 production was diminished by adding an EMMPRIN antibody. EMMPRIN-transfected COS-7 cells stimulated HUCF to predominantly augment proMMP-1 and -3 expressions. A systematic peptide screening method revealed that (42)SLNDSATEVTGHRWLK(57) in the first loop domain of EMMPRIN participated in the augmentation of proMMP-1 production.
CONCLUSIONS: These results provide a novel mechanism of malignancy of uterine cervical carcinoma, in that the augmentation of EMMPRIN expression by tumor-stromal cell interaction progresses tumor invasion along with the increase of MMP expression via an active site of EMMPRIN, (42)SLNDSATEVTGHRWLK(57).

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19427027     DOI: 10.1016/j.ygyno.2009.04.004

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  9 in total

1.  An epitope-specific novel anti-EMMPRIN polyclonal antibody inhibits tumor progression.

Authors:  Miriam Walter; Elina Simanovich; Vera Brod; Nitza Lahat; Haim Bitterman; Michal A Rahat
Journal:  Oncoimmunology       Date:  2015-08-28       Impact factor: 8.110

Review 2.  EMMPRIN in gynecologic cancers: pathologic and therapeutic aspects.

Authors:  Dan-tong Liu
Journal:  Tumour Biol       Date:  2015-05-14

Review 3.  Cyclophilin-CD147 interactions: a new target for anti-inflammatory therapeutics.

Authors:  V Yurchenko; S Constant; E Eisenmesser; M Bukrinsky
Journal:  Clin Exp Immunol       Date:  2010-03-16       Impact factor: 4.330

4.  Expression of extracellular matrix metalloproteinase inducer (EMMPRIN) and its related extracellular matrix degrading enzymes in the endometrium during estrous cycle and early gestation in cattle.

Authors:  Birendra Mishra; Keiichiro Kizaki; Katsuo Koshi; Koichi Ushizawa; Toru Takahashi; Misa Hosoe; Takashi Sato; Akira Ito; Kazuyoshi Hashizume
Journal:  Reprod Biol Endocrinol       Date:  2010-06-11       Impact factor: 5.211

5.  Tumor-derived microvesicles mediate human breast cancer invasion through differentially glycosylated EMMPRIN.

Authors:  Kerstin Menck; Christian Scharf; Annalen Bleckmann; Lydia Dyck; Ulrike Rost; Dirk Wenzel; Vishnu M Dhople; Laila Siam; Tobias Pukrop; Claudia Binder; Florian Klemm
Journal:  J Mol Cell Biol       Date:  2014-12-11       Impact factor: 6.216

6.  Remodeling of extracellular matrix by normal and tumor-associated fibroblasts promotes cervical cancer progression.

Authors:  Alexandra Fullár; József Dudás; Lászlóné Oláh; Péter Hollósi; Zoltán Papp; Gábor Sobel; Katalin Karászi; Sándor Paku; Kornélia Baghy; Ilona Kovalszky
Journal:  BMC Cancer       Date:  2015-04-11       Impact factor: 4.430

7.  Characterisation of tumour-derived microvesicles in cancer patients' blood and correlation with clinical outcome.

Authors:  Kerstin Menck; Annalen Bleckmann; Astrid Wachter; Bianca Hennies; Lena Ries; Matthias Schulz; Marko Balkenhol; Tobias Pukrop; Bawarjan Schatlo; Ulrike Rost; Dirk Wenzel; Florian Klemm; Claudia Binder
Journal:  J Extracell Vesicles       Date:  2017-07-16

Review 8.  Crosstalk between cancer-associated fibroblasts and immune cells in the tumor microenvironment: new findings and future perspectives.

Authors:  Xiaoqi Mao; Jin Xu; Wei Wang; Chen Liang; Jie Hua; Jiang Liu; Bo Zhang; Qingcai Meng; Xianjun Yu; Si Shi
Journal:  Mol Cancer       Date:  2021-10-11       Impact factor: 27.401

9.  Tumor cell-macrophage interactions increase angiogenesis through secretion of EMMPRIN.

Authors:  Bat-Chen Amit-Cohen; Maya M Rahat; Michal A Rahat
Journal:  Front Physiol       Date:  2013-07-12       Impact factor: 4.566

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.